Reimagining Wellness and Healthcare  

We are driven by the exciting and unique goal of revitalizing, repurposing, and reimagining existing therapies to address unmet consumer and patient needs.

Who We Are

Vectura Fertin Pharma brings together Vectura’s expertise in inhalation and Fertin Pharma’s leadership in oral and intra-oral delivery systems to build upon products that exist today and make them better for consumers and patients tomorrow.

We will take proven, safe, and effective therapies, unlock their true potential through the application of new and existing consumer and patient-led delivery systems, and commercialize them through proprietary wellness and healthcare brands or in partnership with other pharmaceutical companies.

Our Key Categories


We will bring to market scientifically substantiated botanical and cannabinoid products that help people take well-being into their own hands in the areas of focus, sleep, energy, and calm.


We will develop and launch fast, effective treatments for cardiovascular emergencies, neurology, and chronic pain management - including medical cannabis - all of which can be delivered via innovative technologies.

ASPRIHALE® is a dry powder inhalation ASA (acetylsalicylic acid) system, which is designed to reduce the severity of heart attacks. By leveraging a self-administered aerosol and using inhalation as the form of medicine (compared with oral tablets), ASPRIHALE® has demonstrated the potential to accelerate the intended effect of ASA with unprecedented speed and so has the potential to minimize the risk of mortality.


Building upon decades of development expertise and experience, the company will continue to develop and grow an independent contract development and manufacturing organization (CDMO) business for inhaled, oral, and intra-oral products and delivery systems, providing consumer and patient-friendly formulations and devices for its customers.

Work With Us

Vectura Fertin Pharma’s ambition is to become a market-leading wellness and healthcare business. We are looking for people from varied backgrounds, with the talent and experience to join us in improving the quality of life for consumers and patients. Be part of our exciting future. 

Our Key People

Meet the senior scientists and leaders guiding Vectura Fertin Pharma.

In early 2022, Vectura Fertin Pharma was formed. Since then, we defined Vectura Fertin Pharma’s operating model. We established the leadership team for this new business, the organizational build-up, decision-making, and scientific governance, as well as key processes.

While owned by PMI, Vectura Fertin Pharma is operationally separate from other businesses owned by PMI. This means that the business has its own executive leadership team overseeing day-to-day operations and a dedicated governance for projects. The business is headed by the President of Vectura Fertin Pharma, although it is collectively delivered with the Vectura Fertin Pharma leadership team, the Vectura Fertin Pharma employees, and a strong investment by PMI to enable the build-out of this business.

Its operational model is based on product categories, led by its category leads. The governance of Vectura Fertin Pharma is designed to enable efficient delivery of the product pipeline and comprises stage-gate review committees, scientific advisory boards, and functional review boards.

Furthermore, revenues generated by Vectura Fertin Pharma are reinvested into its wellness and healthcare business.